12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lomitapide regulatory update

Aegerion said EMA accepted for review an MAA for lomitapide to treat homozygous familial hypercholesterolemia (HoFH). Earlier this month, Aegerion submitted an NDA to FDA for the...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >